Teodor Burtea - Institute Director Council
MRES Stock | USD 0.01 0.0004 4.04% |
Insider
Teodor Burtea is Director Council of Institute of Biomedical
Phone | 382 20 663 075 |
Web | https://mrescorp.com |
Similar Executives
Showing other executives | INSIDER Age | ||
Eric Tse | Sino Biopharmaceutical Ltd | 27 | |
Edith MD | Bolt Biotherapeutics | 67 | |
BSc FRCPath | Achilles Therapeutics PLC | 59 | |
Simon Beaudoin | Defence Therapeutics | 39 | |
Shachar CPA | Enlivex Therapeutics | 47 | |
MBA CFA | Bolt Biotherapeutics | 60 | |
MD FACP | NextCure | 71 | |
Carrie Cesarone | Defence Therapeutics | 58 | |
Sergio Quezada | Achilles Therapeutics PLC | 49 | |
Ming Yin | Bolt Biotherapeutics | N/A | |
Michael MSBA | NextCure | 63 | |
Sebastien Plouffe | Defence Therapeutics | 51 | |
Moutih Rafei | Defence Therapeutics | 41 | |
Lieping MD | NextCure | 67 | |
Solomon Langermann | NextCure | 64 | |
FMEDSCI MD | Achilles Therapeutics PLC | 49 | |
Julia Wilson | Achilles Therapeutics PLC | N/A | |
CPA CPA | NextCure | 61 | |
Karl MD | Achilles Therapeutics PLC | 57 | |
Oren Hershkovitz | Enlivex Therapeutics | 47 | |
Karen Bergman | Bolt Biotherapeutics | N/A |
Institute of Biomedical Leadership Team
Elected by the shareholders, the Institute's board of directors comprises two types of representatives: Institute inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Institute. The board's role is to monitor Institute's management team and ensure that shareholders' interests are well served. Institute's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Institute's outside directors are responsible for providing unbiased perspectives on the board's policies.
Teodor Burtea, Director Council | ||
Drasko Pekovic, Chairman, Founder |
Institute Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Institute a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Current Valuation | 198.84 K | |||
Shares Outstanding | 66.28 M | |||
Price To Book | 0.69 X | |||
Revenue | 1.41 M | |||
Net Income | 564.67 K | |||
Cash Flow From Operations | 2.06 M | |||
Beta | 1.71 | |||
Market Capitalization | 639.61 K | |||
Total Asset | 5.28 M | |||
Retained Earnings | (55.58 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Institute Pink Sheet Analysis
When running Institute's price analysis, check to measure Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Institute is operating at the current time. Most of Institute's value examination focuses on studying past and present price action to predict the probability of Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Institute's price. Additionally, you may evaluate how the addition of Institute to your portfolios can decrease your overall portfolio volatility.